ÀϽÃ: : 2012³â 3¿ù 16ÀÏ ±Ý¿äÀÏ
Àå¼Ò: ¼¿ï ±×·£µå ÀÎÅÍÄÜƼ³ÙÅ» È£ÅÚ
1ºÎ: Ãá°è °£ÀÌ½Ä ¿¬±¸È¸ Áý´ãȸ (6:30 – 7:30)
ÁÖÁ¦: Transition from CTP to MELD – ½ÉÃþ ÆгÎÅäÀÇ (ÁÂÀå: À̼®±¸)
6:30-6:45: MELDÀÇ °³¹ß ¹è°æ°ú Çѱ¹Çü MELD system ÃÊ¾È ¼Ò°³ (¿¬¼¼´ë ±è¸í¼ö) 15ºÐ
6:45-7:15 MELDÀüȯÀÇ ¸ðÀÇ ºÐ¼®
- 1±Ç¿ª multi-center ÀÚ·á ºÐ¼® (¼¿ï¾Æ»êº´¿ø Ȳ½Å)
- 1±Ç¿ª medium-volume center ÀÇ°ß (°í·Á´ë ±èµ¿½Ä)
- 2/3±Ç¿ª center ÀÇ°ß (ÀüºÏ´ë À¯Èñö)
7:15-7:30 MELD ÃÊ¾È º¸¿Ï ¹× ¸ðÀÇ Àû¿ë¿¡ ´ëÇÑ ÆгΠÅäÀÇ
2ºÎ: Innovative ABCD meeting (Sponsored by Novartis) (7:30 – 9:00 PM)
ÁÖÁ¦: Are we satisfied with current long-term outcome in Liver Transplantation? (ÁÂÀå: À̼®±¸, ±èµ¿±¸)
7:30-7:40 Welcome and Opening
7:40-8:20 The beneficial effect of CsA in liver transplantation and IS management for risk factor (focusing on DM, CV risk and HCV)
(Gary Levy, University of Toronto)
8:20-9:00 Prevention and treatment of HCC recurrence in the era of transplant benefit
(Umberto Cillo, University of Padua)
9:00-10:00 Management in real practice (Case review
À̱¤¿õ (¼¿ï´ë), ¼Û±â¿ø (¼¿ï¾Æ»êº´¿ø), ±ÇÁØÇõ (¼¿ï»ï¼ºº´¿ø) |